UNSPSC 51422431: Hydrocortisone phosphate

This classification denotes a therapeutic hydrocortisone with the molecular formula C21H31O8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Y87E22X71, chemically known as pregn-4-ene-3,20-dione, 11, 17-dihydroxy-21- (phosphonooxy)-, (11.beta.)- but more generally known as hydrocortisone phosphate, which bears US NIH Compound Identifier 3645. Most nations, for tariff and trade purposes, schedule hydrocortisone phosphate under HS 29372100 and SITC 54153.

As of Q4 2014, HYDROCORTISONE PHOSPHATE remains US FDA's Preferred Term for this commodity. Hydrocortisone phosphate bears US NLM identifiers UMLS ID C0056383 and NCI Concept Code C83763. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COP(=O)(O)O)O)C)O.

UNSPSC 51422431 Hydrocortisone phosphate is a Commodity code that presents a mismatch between its nominal scope and recent state and local procurement activity. The code's title refers to a specific pharmaceutical product, yet the two recent solicitations tagged under it—a Seminole County, Florida IFB for naloxone and drug deactivation systems, and a Texas Health and Human Services Commission RFI for direct-to-manufacturer prescription program infrastructure—address broader pharmacy procurement, pharmaceutical distribution models, and emergency-response medications rather than hydrocortisone phosphate specifically. The actual buying pattern under this code reflects state and local demand for emergency pharmaceuticals, pharmacy benefit management alternatives, and prescription fulfillment systems that serve public health and state employee benefit programs.

Recent activity is geographically dispersed across Florida and Texas, with issuing bodies spanning county health departments and state health and human services agencies. Seminole County's IFB, posted June 30, 2026 with a response deadline of July 26, 2023, solicits 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the county's community health building, with all shipping and delivery costs included in pricing. The Texas Health and Human Services Commission's RFI, posted April 3, 2026 with an April 3, 2026 response deadline, is gathering market intelligence on vendors' capacity to establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler arrangements, focusing on vendors' experience with self-insured employer contracts, negotiated net pricing models, and value-based agreements. Neither solicitation specifies budget ranges or set-aside designations, though the Seminole County contract includes a two-year initial term with one-year renewal option and requires E-Verify compliance and drug-free workplace certification.